Ishara Investments LP
An institutional investment manager in LOS ANGELES, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2111609.
- Reported value$136.1m
- Positions41
Holdings: 41 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals IncACAD | COM | 004225108 | 10.4 | 7.6% | 410,000 | Added+287,000 | |
| Xeris Biopharma Holdings IncXERS | COM | 98422E103 | 9.7 | 7.2% | 1,230,000 | Added+205,000 | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 8.2 | 6.0% | 143,500 | Added+61,500 | |
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 7.5 | 5.5% | 22,550 | Unchanged | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 6.8 | 5.0% | 205,000 | Added+30,750 | |
| Agios Pharmaceuticals IncAGIO | COM | 00847X104 | 6.1 | 4.5% | 164,000 | New+164,000 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 5.5 | 4.0% | 51,250 | New+51,250 | |
| Crinetics Pharmaceuticals in | COM | 22663K107 | 5.4 | 3.9% | 143,500 | New+143,500 | |
| Zentalis Pharmaceuticals IncZNTL | COM | 98943L107 | 5.0 | 3.7% | 1,025,000 | Reduced−205,000 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 4.8 | 3.5% | 82,000 | Added+24,600 | |
| Annexon IncANNX | COM | 03589W102 | 4.7 | 3.4% | 820,000 | Added+645,750 | |
| Travere Therapeutics IncTVTX | COM | 89422G107 | 4.7 | 3.4% | 82,000 | Reduced−28,700 | |
| Tonix Pharmaceuticals HLDG CTNXP | COM NEW | 890260839 | 4.3 | 3.2% | 338,250 | New+338,250 | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 4.3 | 3.1% | 57,400 | New+57,400 | |
| Axsome Therapeutics Inc.AXSM | COM | 05464T104 | 4.0 | 2.9% | 16,400 | Reduced−24,600 | |
| Contineum Therapeutics IncCTNM | CL A | 21217B100 | 3.4 | 2.5% | 205,000 | Added+63,000 | |
| Lexicon Pharmaceuticals IncLXRX | COM NEW | 528872302 | 3.1 | 2.2% | 1,271,000 | Added+369,000 | |
| Kura Oncology IncKURA | COM | 50127T109 | 3.0 | 2.2% | 276,750 | New+276,750 | |
| DBV Technologies S aDBVT | SPONSORED ADS | 23306J309 | 3.0 | 2.2% | 184,500 | Added+82,000 | |
| Genmab A/SGMAB | SPONSORED ADS | 372303206 | 2.8 | 2.1% | 102,500 | Added+20,500 | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 2.8 | 2.1% | 32,800 | New+32,800 | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 2.8 | 2.0% | 102,500 | Added+20,500 | |
| Silence Therapeutics plcSLN | ADS | 82686Q101 | 2.4 | 1.8% | 55,350 | Reduced−85,150 | |
| Nuvation Bio IncNUVB | COM CL A | 67080N101 | 2.1 | 1.5% | 369,000 | New+369,000 | |
| Wave Life Sciences Ltd | SHS | Y95308105 | 1.9 | 1.4% | 328,000 | New+328,000 | |
| Nektar TherapeuticsNKTR | COM NEW | 640268306 | 1.9 | 1.4% | 26,650 | New+26,650 | |
| Scholar Rock HLDG CorpSRRK | COM | 80706P103 | 1.7 | 1.2% | 30,750 | Reduced−26,650 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 1.7 | 1.2% | 32,800 | New+32,800 | |
| Alnylam Pharmaceuticals IncALNY | COM | 02043Q107 | 1.5 | 1.1% | 5,125 | Unchanged | |
| Beam Therapeutics IncBEAM | COM | 07373V105 | 1.4 | 1.0% | 41,000 | Reduced−16,400 | |
| Sionna Therapeutics IncSION | COM | 829401108 | 1.4 | 1.0% | 123,000 | Added+73,800 | |
| Oric Pharmaceuticals IncORIC | COM | 68622P109 | 1.3 | 1.0% | 123,000 | Added+20,500 | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 1.3 | 0.9% | 36,900 | Unchanged | |
| Vertex Pharmaceuticals IncVRTX | COM | 92532F100 | 1.2 | 0.9% | 2,460 | New+2,460 | |
| ARS Pharmaceuticals IncSPRY | COM | 82835W108 | 1.1 | 0.8% | 143,490 | New+143,490 | |
| Monopar Therapeutics IncMNPR | COM NEW | 61023L207 | 1.1 | 0.8% | 12,300 | New+12,300 | |
| Erasca IncERAS | COM | 29479A108 | 0.8 | 0.6% | 41,000 | New+41,000 | |
| Vera Therapeutics IncVERA | CL A | 92337R101 | 0.4 | 0.3% | 10,250 | Reduced−71,750 | |
| Immatics N.V | SHS | N44445109 | 0.3 | 0.2% | 30,750 | Reduced−123,000 | |
| Mereo Biopharma Group plcMREO | SPON ADS | 589492107 | 0.2 | 0.2% | 768,750 | New+768,750 | |
| Gossamer Bio Inc | COM | 38341P102 | 0.1 | <0.1% | 820,000 | Unchanged |
Sold out: 12 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutic | COM | 03152W109 | 0.0 | 0.0% | 0 | Sold out−369,000 | |
| Ardelyx IncARDX | COM | 039697107 | 0.0 | 0.0% | 0 | Sold out−451,000 | |
| Arrowhead Pharmaceuticals inARWR | COM | 04280A100 | 0.0 | 0.0% | 0 | Sold out−55,350 | |
| Catalyst Pharmaceuticals Inc | COM | 14888U101 | 0.0 | 0.0% | 0 | Sold out−82,000 | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 0.0 | 0.0% | 0 | Sold out−49,200 | |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 0.0 | 0.0% | 0 | Sold out−24,600 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−276,750 | |
| Ligand Pharmaceuticals IncLGND | COM NEW | 53220K504 | 0.0 | 0.0% | 0 | Sold out−8,200 | |
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 0.0 | 0.0% | 0 | Sold out−174,250 | |
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 0.0 | 0.0% | 0 | Put | Sold out−20,500 |
| PTC Therapeutics IncPTCT | COM | 69366J200 | 0.0 | 0.0% | 0 | Sold out−10,250 | |
| Verastem IncVSTM | COM NEW | 92337C203 | 0.0 | 0.0% | 0 | Sold out−820,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0002111609-26-000004 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.